

We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

4,800

Open access books available

122,000

International authors and editors

135M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities



WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.

For more information visit www.intechopen.com



Potential Benefit of Mineralocorticoid Receptor Antagonists in Kidney Diseases

Jonatan Barrera-Chimal, Lionel Lattenist and Frederic Jaisser

Abstract

Since the last two decades, a major paradigm shift occurred in our understanding of the physiological and pathophysiological roles of the mineralocorticoid receptor (MR). Expression of the MR in cells/tissues not involved in sodium/potassium balance and extracellular volume homeostasis, i.e., the primary role of the aldosterone/MR complex, paved the way to the discovery of unsuspected implications of MR in a variety of cellular processes and pathological consequences. It also opens the possibility for quick translation to the bedside using available MR antagonists (MRAs) such as spironolactone, canrenone, or eplerenone or using the more recently developed various nonsteroidal MRAs that are not yet marketed. Landmark clinical trials like RALES, EPHESUS, or EMPHASIS well established that MRAs provide great benefits in patients with heart failure and spironolactone or eplerenone have been recommended in these patients. The deep understanding provided by preclinical studies in various domains stimulated the possibility to extend the use of MRAs to new fields, including renal diseases even if MRAs are currently contraindicated or used with great caution in patients with renal function impairment due to the higher risk of hyperkalemia associated with MRA therapy in this at-risk population. The present review presents preclinical data supporting potential indications in renal diseases.

Keywords: aldosterone, renal, hypertension

1. Pathophysiological basis: MR activation in the kidney—where and what are the consequences?

1.1 MR expression in the kidney

Besides the well-known expression of MR in the so-called aldosterone-sensitive distal nephron (ASDN) encompassing DCT1-2, CNT, and CDD, MR is also expressed in a variety of other cell types within the kidney [1–5]. In basal condition, MR is expressed in the vasculature in both endothelium [6] and smooth muscle cells [1]. MR expression has also been reported in the mesangium [7], podocytes [8], fibroblasts [9], and immune cells (macrophages, dendritic cells, T lymphocytes) [10–13]. In **Figure 1**, we summarize the effects reported for MR antagonists in different target cells within the kidney that represent potential




Figure 1. *MR antagonists display beneficial effects against kidney diseases by acting in several cell types and by different mechanisms.*

beneficial mechanisms acting against kidney disease progression, and that will be detailed below. It is important to mention that MR expression might be upregulated in some pathological conditions such as diabetes [14], heavy proteinuria [15], vascular aging [16], and hypertension [17], leading to potential increased MR signaling. The specific physiological role of MR in the cells where its expression has been reported remains to be elucidated; however, it was recently proposed that MR in endothelial, smooth muscle, and inflammatory cells may be an evolutionary mechanism to prevent hemorrhage by promoting vasoconstriction and thrombosis and to promote wound healing by the activation of inflammation and vascular remodeling [18].

1.2 MR activation: what is the ligand?

The classical ligand of the MR is aldosterone, but glucocorticoids can bind with similar affinity with that of MR. Of note ligand-receptor dissociation is faster for glucocorticoid than aldosterone, resulting in higher transactivation potency for aldosterone as compared to glucocorticoids, especially at low concentration. However, a selectivity mechanism allows aldosterone to preferentially activate the MR in the presence of glucocorticoids, despite much higher local concentration of glucocorticoids than aldosterone. The 11β -hydroxysteroid dehydrogenase type 2 (11β -HSD2) converts corticosterone/cortisol to compounds with low affinity for the MR [19]. The cellular aldosterone/glucocorticoid selectivity therefore depends on the expression level/activity of the HSD2. In the kidney, cells from the ASDN and endothelium express HSD2, while this is debated for the smooth muscle cells [20]. In podocytes, mesangial cells, and immune cells, for example, HSD2 is not expressed, therefore supporting the fact that glucocorticoids may be the main ligands of MR in these cells. It should be stressed, however, that there may be species differences as well as induction of HSD2 expression in some pathological conditions, allowing aldosterone to activate MR. This has not been carefully analyzed yet [1].

1.3 Major pathophysiological mechanisms involved in MR and kidney diseases

1.3.1 MR and renal hemodynamic alterations

Experimental evidence in rodent models of acute kidney injury (AKI) supports the concept that MR contributes to vascular tone regulation [1]. The benefit of MRA in renal ischemia-reperfusion injury is associated with improved renal hemodynamics and decreased renal vascular resistance [21, 22]. We recently showed that MR expressed in mouse smooth muscle cells contributes to renal injury induced by ischemia (through a mechanism involving oxidative stress and Rac1 activation) [23], as well as in acute CsA nephrotoxicity (due to increased vascular L-type calcium channel activity thereby resulting in decreased renal artery vasoconstriction and overall improvement in renal hemodynamics) [24]. Of note, the endothelial MR was not directly involved since endothelial MR gene inactivation had no effect in ischemia-reperfusion or CsA-induced renal injuries [23, 24]. Whether MR expressed in the renal vasculature contributes to renal injury in other settings like diabetes or chronic kidney diseases remains to be explored.

1.3.2 MR and oxidative stress

Multiple *in vitro* and *in vivo* studies have shown the significance of oxidative stress induced by aldosterone/MR and its detrimental consequences on kidney injury. *In vivo*, the DOCA-salt causes oxidative DNA damage [25], and aldosterone infusion produces an MR-dependent increase in NADPH oxidase activity and ROS generation in the kidney [26, 27]. MR expressed in the smooth muscle cell may have a major role as we recently demonstrated in ischemia-reperfusion injury using smooth muscle MR KO mice [23]. In vascular cells, aldosterone increased ROS which in turn modifies the cysteinyl thiols in the eNOS-activating region of endothelin-1 B receptor to decrease endothelin-1-stimulated eNOS activity, impairing the vasodilatory pathway. These effects have repercussions on renal hemodynamics and function in kidney ischemia/reperfusion injury in both rat and mouse [21–23]. In rat mesangial cells, aldosterone directly stimulates superoxide anion generation, which is accompanied by an increase in NADPH oxidase activity and translocation of p47phox and p67phox to the cell membrane [28]. Moreover, recent studies have shown that aldosterone induces mesangial cell apoptosis and that the administration of an antioxidant or MR antagonist attenuates the proapoptotic effects of aldosterone [29]. The increase in NADPH oxidase Nox2 plasma levels and urinary isoprostanes is also observed in patients with primary aldosteronism as compared to essential hypertensive patients [30]. Interestingly, adrenalectomy is associated with a reduction in both parameters [30]. Moreover, therapeutic MR antagonism reduced oxidative stress in diabetic [31] or kidney transplant patients [32].

1.3.3 MR and inflammation

A role for MR signaling in inflammation has been suggested since early studies showing that the treatment of rats with aldosterone and salt causes perivascular leukocyte infiltration and increased expression of inflammatory markers [1]. More recently, macrophages, dendritic cells, and T lymphocytes have been identified as MR-expressing cells [1, 11, 33]. The use of genetically modified mouse model deficient of MR in myeloid cells revealed that myeloid MR contributes to renal injury in a glomerulonephritis mouse model [8]. Moreover, our recent work showed that myeloid MR participates to CKD progression induced by AKI [34].

The deletion of MR in myeloid cells favored M2 polarization of renal macrophages leading to improved tissue repair and prevention of renal scarring, decreased function, and interstitial fibrosis. Interestingly MRA administration using the nonsteroidal MRA finerenone has similar effects, blunting CKD development after ischemia-reperfusion injury in rodents [22, 34] and in the large white pig [34]. The role of myeloid MR in the progression of CKD in other models of kidney disease has to be further studied. The role of MR expressed in T cell has not been explored in kidney disease. However, T-cell MR knockout mice prevented cardiac hypertrophy, fibrosis, and dysfunction compared with littermate control mice after abdominal aortic constriction suggesting that MR in T cells may also play a pro-inflammatory role [13]. In dendritic cells, MR stimulation with aldosterone induces the secretion of IL-6 and TGF- β , two pro-inflammatory cytokines able to polarize the adaptive immune response toward a Th17 phenotype [35]. MR antagonism with spironolactone reduced heart and kidney damage in a hypertension rat model due to blockade of Th17 polarization and the induction of regulatory T cells [36]. Pharmacological MR blockade improves the chronic inflammatory state associated with CV disease [1, 33]. Altogether, these data suggest that aldosterone/MR modulates innate and adaptive immunity, which may have a critical role in end-organ damage.

1.3.4 MR and fibrosis

Fibrosis and extracellular matrix remodeling is a well-documented effect of MR activation in various tissues, including the kidney [1]. Aldosterone induces pro-fibrotic cytokine production and accumulation of collagen and other extracellular matrix components [9, 37, 38]. Aldosterone administration is associated with an increase in renal TGF- β , collagen, and connective tissue growth factor expression and medullary and cortical fibrosis [39]. Aldosterone also influences the production of plasminogen activator inhibitor-1 leading to glomerulosclerosis [40]. MR activation in renal fibroblasts results in rapid activation of growth factor receptors and induction of PI3K/MAPK signaling, which stimulates proliferation and therefore contributes to fibrosis expansion [41]. Several molecular MR targets may be involved in the pro-fibrotic response of Aldo/MR signaling. We recently deeply explored the role of neutrophil gelatinase-associated lipocalin (NGAL) that we identified as a novel aldosterone/MR target [42]. NGAL induction by the MR might be a mechanism for MR-induced fibrosis since mice deficient in NGAL are protected from aldosterone-induced kidney fibrosis (Jaisser, unpublished data). Galectin-3 also mediates the pro-fibrotic effects of aldosterone-MR, and galectin-3 KO mice are protected against aldosterone-induced kidney fibrosis [43]. Taken together increased MR activation which may promote kidney fibrosis by inducing fibroblast proliferation and the production of several pro-fibrotic molecules.

2. Preclinical data supporting the benefit of MR antagonists (MRA) in kidney diseases

2.1 Benefit of MRA on acute kidney injury (AKI) induced by ischemia/reperfusion (IR)

A reduction of renal blood flow is occurring in several clinical settings, and this is a major cause of AKI. A number of studies in rodents and in the Large White Pig preclinical model have shown that MR antagonism with steroidal and nonsteroidal MRAs prevents and treats AKI induced by IR. In an early study, it was shown that spironolactone is a useful strategy to prevent the acute kidney dysfunction and

tubular injury induced by bilateral renal IR injury in the rat [44]. The sustained reduction in renal blood flow observed after 24 hours in the IR-untreated rats was prevented in the spironolactone-treated groups. This was reproduced using nonsteroidal MRAs in both rats and mice [21–23] leading to the discovery of a novel underlying mechanism related to the limitation of oxidative stress and impaired endothelin-B receptor signaling [21, 22]. Importantly MRA also have curative effects when administered within the first 3 hours post ischemia-reperfusion [21, 45, 46]. The benefit of MR antagonists in ischemic AKI was translated into the Large White Pig preclinical model in which MR antagonism with soludactone (potassium canrenoate, a soluble MRA used in clinics) prevented the effects of AKI including kidney dysfunction and structural injuries [23].

2.2 AKI to CKD transition

In recent years, special focus has been given to the chronic consequences of an AKI episode. Several clinical and experimental studies have shown that AKI is linked with increased risk for CKD development.

In the rat, CKD progression induced by a single event of ischemic AKI (characterized by proteinuria, kidney dysfunction, and severe structural injury including interstitial fibrosis, glomerulosclerosis, tubule dilation, and podocyte injury) is prevented by spironolactone [45] and finerenone [22, 47]. MR antagonism also prevents CKD induced by a mild ischemic period even when administered 3 hours after the ischemia episode [48]. The underlying mechanisms rely on the limitation of inflammatory events and the promotion of repair mechanisms held by M2-type macrophages and interleukin-4 receptor signaling [34]. Importantly, these benefits are also observed in the Large White Pig model: short-term soludactone administration before/after the ischemic event indeed prevents CKD progression at 3 months, with a reduction in fibrosis and proteinuria and improved renal function [34]. The data indicate that MRA treatment is an encouraging therapeutic option to prevent the AKI to CKD transition which identifies the MR expressed in inflammatory cells as a specific target in this setting.

2.3 MR antagonism in kidney fibrosis and CKD progression

Kidney fibrosis is a common endpoint of CKD from different origins. Accumulating evidences indicate that aldosterone and/or MR signaling plays a key role in CKD development in a number of animal models including nephron reduction [49, 50], hypertensive models [51, 52], unilateral ureteral obstruction [53, 54], and mineralocorticoid/salt models [55]. MR antagonism not only prevents glomerulosclerosis in the remnant kidney model but also induces regression of glomerulosclerosis as evidenced by Aldigier et al. on kidney biopsy 4 weeks after spironolactone treatment initiation in rats already presenting CKD [56]. Eplerenone also limited proteinuria in this model [50]. Renal injury observed in the Dahl-sensitive rat upon salt loading is greatly limited by eplerenone [57, 58] and the nonsteroidal MRA CS-3150 [59]. This may be related to a direct effect on podocyte, as underlined by Shibata et al., involving activation of Rac1 and possible increased Rac1-mediated transactivation of the podocyte MR [60].

2.4 Benefit of MR blockade in diabetic nephropathy

The beneficial effects of MRA in different models of type I and type II diabetic nephropathy or kidney injury related to metabolic disorders have been reported. Spironolactone administration for 3 weeks reduced renal collagen deposition in

STZ-induced diabetic rats [61]. This was thereafter reported for other MRAs such as eplerenone [62]. MRAs are also efficient in limiting progression of diabetic nephropathy in models of type 2 diabetes. Eplerenone reduced albuminuria, glomerular hypertrophy, and mesangial expansion in the db/db mouse model [62]. The novel nonsteroidal MRA AZ9977 has similar effects [63]. In the Otsuka Long-Evans Tokushima Fatty (OLETF) rats or Zucker obese rats, similar benefits have been reported after MRA treatment [64, 65].

2.5 Calcineurin inhibitor toxicity and kidney transplantation

Some studies showed a benefit of MR blockade in acute and chronic CsA nephrotoxicity, including effects on preventing structural and functional alterations [66–68]. The underlying mechanisms leading to this protection rely on hemodynamic effects (blunting the sustained vasoconstriction induced by CNI) [24, 68] or renal extracellular matrix remodeling [67]. The effect of MRA in experimental kidney transplantation has been tested in a model of chronic allograft dysfunction in the Dark-Agouti to Wistar-Furth rat with a reduced vasculopathy and glomerular macrophage influx and a trend to reduced proteinuria and glomerulosclerosis [69].

2.6 Glomerulonephritis and MR blockade

Although few studies have addressed this issue, it has been reported that spironolactone and the nonsteroidal MRA BR-4628 are beneficial in mouse models of glomerulonephritis [70–72]. The myeloid MR seems to play a key role in the kidney since genetic deletion of MR in myeloid cells, but not in podocyte, blunted glomerulonephritis development [8].

3. Conclusion

Preclinical evidences clearly support the concept of a benefit of MR antagonism to treat or delay kidney diseases from different origins including ischemic kidney disease, diabetic and hypertensive nephropathy, glomerulonephritis, and calcineurin inhibitor toxicity in the context of kidney transplant. The underlying mechanisms rely on improving local hemodynamics and reducing extracellular matrix remodeling and local inflammation (**Figure 1**). Whether this translates in clinics is already largely supported by several clinical trials, but definitive answers should be provided by well-designed, large clinical trials based on hard renal outcomes like limitation of CKD progression and/or cardiovascular outcomes. A recent study showed that in patients with heart failure with preserved ejection fraction, spironolactone treatment decreased the relative risk for cardiovascular death, heart failure hospitalization, or aborted cardiac arrest, despite an increase in the hyperkalemia risk [73]. Novel therapeutics limiting the risk of hyperkalemia upon MRA use is also warranted in these at-risk populations.

Acknowledgements

This publication is based upon the work from the EU COST Action ADMIRE BM1301 in Aldosterone and Mineralocorticoid Receptor Physiology and Pathophysiology (www.admirecosteu.com). The authors' work was supported by grants from the Institut National de la Santé et de la Recherche Médicale, the Centre de Recherche Industrielle et Technique, the Agence Nationale de la

Recherche (ANR-16-CE14-0021-01), the French Medical Research Foundation (DEQ20160334885), and the National Autonomous University of Mexico—DGAPA—PAPIIT (IA200117 and IN202919 to JBC) and a public grant Fight-HF overseen by the French National Research Agency (ANR) as part of the “Investissements d’Avenir” program (reference: ANR-15-RHU-0004).

IntechOpen

Author details

Jonatan Barrera-Chimal¹, Lionel Lattenist² and Frederic Jaisser^{2,3*}


¹ Laboratorio de Fisiología Cardiovascular y Trasplante Renal, Unidad de Medicina Traslacional, Instituto de Investigaciones Biomédicas, Instituto Nacional de Cardiología Ignacio Chávez, Universidad Nacional Autónoma de México, Mexico City, Mexico

² Clinical Investigation Centre, Lorraine University, Vandoeuvre-lès-Nancy, France

³ Centre de Recherche des Cordeliers, Sorbonne University, Paris Descartes University, Paris, France

*Address all correspondence to: frederic.jaisser@inserm.fr

IntechOpen

© 2019 The Author(s). Licensee IntechOpen. Distributed under the terms of the Creative Commons Attribution - NonCommercial 4.0 License (<https://creativecommons.org/licenses/by-nc/4.0/>), which permits use, distribution and reproduction for non-commercial purposes, provided the original is properly cited. 

References

- [1] Jaisser F, Farman N. Emerging roles of the mineralocorticoid receptor in pathology: Toward new paradigms in clinical pharmacology. *Pharmacological Reviews*. 2016;**68**(1):49-75
- [2] Kolkhof P, Barfacker L. 30 years of the mineralocorticoid receptor: Mineralocorticoid receptor antagonists: 60 years of research and development. *The Journal of Endocrinology*. 2017;**234**(1):T125-T140
- [3] Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. *The New England Journal of Medicine*. 1999;**341**(10):709-717
- [4] Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. *The New England Journal of Medicine*. 2003;**348**(14):1309-1321
- [5] Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. *The New England Journal of Medicine*. 2011;**364**(1):11-21
- [6] Caprio M, Newfell BG, la Sala A, et al. Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion. *Circulation Research*. 2008;**102**(11):1359-1367
- [7] Nishiyama A, Yao L, Fan Y, et al. Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability. *Hypertension*. 2005;**45**(4):710-716
- [8] Huang LL, Nikolic-Paterson DJ, Han Y, et al. Myeloid mineralocorticoid receptor activation contributes to progressive kidney disease. *Journal of the American Society of Nephrology*. 2014;**25**(10):2231-2240
- [9] Nagai Y, Miyata K, Sun GP, et al. Aldosterone stimulates collagen gene expression and synthesis via activation of ERK1/2 in rat renal fibroblasts. *Hypertension*. 2005;**46**(4):1039-1045
- [10] Belden Z, Deiuliis JA, Dobre M, Rajagopalan S. The role of the mineralocorticoid receptor in inflammation: Focus on kidney and vasculature. *American Journal of Nephrology*. 2017;**46**(4):298-314
- [11] Bene NC, Alcaide P, Wortis HH, Jaffe IZ. Mineralocorticoid receptors in immune cells: Emerging role in cardiovascular disease. *Steroids*. 2014;**91**:38-45
- [12] Rickard AJ, Morgan J, Tesch G, Funder JW, Fuller PJ, Young MJ. Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure. *Hypertension*. 2009;**54**(3):537-543
- [13] Sun XN, Li C, Liu Y, et al. T-cell mineralocorticoid receptor controls blood pressure by regulating interferon-gamma. *Circulation Research*. 2017;**120**(10):1584-1597
- [14] Taira M, Toba H, Murakami M, et al. Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats. *European Journal of Pharmacology*. 2008;**589**(1-3):264-271
- [15] Quinkler M, Zehnder D, Eardley KS, et al. Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with

heavy proteinuria. *Circulation*. 2005;**112**(10):1435-1443

[16] Krug AW, Allenhofer L, Monticone R, et al. Elevated mineralocorticoid receptor activity in aged rat vascular smooth muscle cells promotes a proinflammatory phenotype via extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase and epidermal growth factor receptor-dependent pathways. *Hypertension*. 2010;**55**(6):1476-1483

[17] DeLano FA, Schmid-Schonbein GW. Enhancement of glucocorticoid and mineralocorticoid receptor density in the microcirculation of the spontaneously hypertensive rat. *Microcirculation*. 2004;**11**(1):69-78

[18] Biwer LA, Wallingford MC, Jaffe IZ. Vascular mineralocorticoid receptor: Evolutionary mediator of wound healing turned harmful by our modern lifestyle. *American Journal of Hypertension*. 2019;**32**(2):123-134

[19] Farman N, Rafestin-Oblin ME. Multiple aspects of mineralocorticoid selectivity. *American Journal of Physiology. Renal Physiology*. 2001;**280**(2):F181-F192

[20] Odermatt A, Kratschmar DV. Tissue-specific modulation of mineralocorticoid receptor function by 11beta-hydroxysteroid dehydrogenases: An overview. *Molecular and Cellular Endocrinology*. 2012;**350**(2):168-186

[21] Barrera-Chimal J, Prince S, Fadel F, et al. Sulfenic acid modification of endothelin B receptor is responsible for the benefit of a nonsteroidal mineralocorticoid receptor antagonist in renal ischemia. *Journal of the American Society of Nephrology*. 2016;**27**(2):398-404

[22] Lattenist L, Lechner SM, Messaoudi S, et al. Nonsteroidal mineralocorticoid receptor antagonist finerenone

protects against acute kidney injury-mediated chronic kidney disease: Role of oxidative stress. *Hypertension*. 2017;**69**(5):870-878

[23] Barrera-Chimal J, Andre-Gregoire G, Nguyen Dinh Cat A, et al. Benefit of mineralocorticoid receptor antagonism in AKI: Role of vascular smooth muscle Rac 1. *Journal of the American Society of Nephrology*. 2017;**28**(4):1216-1226

[24] Amador CA, Bertocchio JP, Andre-Gregoire G, et al. Deletion of mineralocorticoid receptors in smooth muscle cells blunts renal vascular resistance following acute cyclosporine administration. *Kidney International*. 2016;**89**(2):354-362

[25] Schupp N, Kolkhof P, Queisser N, et al. Mineralocorticoid receptor-mediated DNA damage in kidneys of DOCA-salt hypertensive rats. *The FASEB Journal*. 2011;**25**(3):968-978

[26] Shibata S, Nagase M, Yoshida S, Kawachi H, Fujita T. Podocyte as the target for aldosterone: Roles of oxidative stress and Sgk 1. *Hypertension*. 2007;**49**(2):355-364

[27] Nishiyama A, Yao L, Nagai Y, et al. Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats. *Hypertension*. 2004;**43**(4):841-848

[28] Miyata K, Rahman M, Shokoji T, et al. Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in rat mesangial cells. *Journal of the American Society of Nephrology*. 2005;**16**(10):2906-2912

[29] Mathew JT, Patni H, Chaudhary AN, et al. Aldosterone induces mesangial cell apoptosis both *in vivo* and *in vitro*. *American Journal of Physiology. Renal Physiology*. 2008;**295**(1):F73-F81

- [30] Petramala L, Pignatelli P, Carnevale R, et al. Oxidative stress in patients affected by primary aldosteronism. *Journal of Hypertension*. 2014;**32**(10):2022-2029. discussion 2029
- [31] Takebayashi K, Matsumoto S, Aso Y, Inukai T. Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. *The Journal of Clinical Endocrinology and Metabolism*. 2006;**91**(6):2214-2217
- [32] Ojeda-Cervantes M, Barrera-Chimal J, Alberu J, Perez-Villalva R, Morales-Buenrostro LE, Bobadilla NA. Mineralocorticoid receptor blockade reduced oxidative stress in renal transplant recipients: A double-blind, randomized pilot study. *American Journal of Nephrology*. 2013;**37**(5):481-490
- [33] Girerd S, Frimat L, Ducloux D, et al. EPURE transplant (eplerenone in patients undergoing renal transplant) study: Study protocol for a randomized controlled trial. *Trials*. 2018;**19**(1):595
- [34] Barrera-Chimal J, Rocha L, Amador-Martinez I, et al. Delayed spironolactone administration prevents the transition from acute kidney injury to chronic kidney disease through improving renal inflammation. *Nephrology, Dialysis, Transplantation*. 2018;**33**(12):2080-2091
- [35] Herrada AA, Contreras FJ, Marini NP, et al. Aldosterone promotes autoimmune damage by enhancing Th17-mediated immunity. *Journal of Immunology*. 2010;**184**(1):191-202
- [36] Amador CA, Barrientos V, Pena J, et al. Spironolactone decreases DOCA-salt-induced organ damage by blocking the activation of T helper 17 and the downregulation of regulatory T lymphocytes. *Hypertension*. 2014;**63**(4):797-803
- [37] Martin-Fernandez B, Rubio-Navarro A, Cortegano I, et al. Aldosterone induces renal fibrosis and inflammatory M1-macrophage subtype via mineralocorticoid receptor in rats. *PLoS One*. 2016;**11**(1):e0145946
- [38] Chen D, Chen Z, Park C, et al. Aldosterone stimulates fibronectin synthesis in renal fibroblasts through mineralocorticoid receptor-dependent and independent mechanisms. *Gene*. 2013;**531**(1):23-30
- [39] Sun Y, Zhang J, Zhang JQ, Ramires FJ. Local angiotensin II and transforming growth factor-beta 1 in renal fibrosis of rats. *Hypertension*. 2000;**35**(5):1078-1084
- [40] Brown NJ, Nakamura S, Ma L, et al. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis *in vivo*. *Kidney International*. 2000;**58**(3):1219-1227
- [41] Huang LL, Nikolic-Paterson DJ, Ma FY, Tesch GH. Aldosterone induces kidney fibroblast proliferation via activation of growth factor receptors and PI3K/MAPK signalling. *Nephron. Experimental Nephrology*. 2012;**120**(4):e115-e122
- [42] Latouche C, El Moghrabi S, Messaoudi S, et al. Neutrophil gelatinase-associated lipocalin is a novel mineralocorticoid target in the cardiovascular system. *Hypertension*. 2012;**59**(5):966-972
- [43] Calvier L, Martinez-Martinez E, Miana M, et al. The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries. *JACC: Heart Failure*. 2015;**3**(1):59-67
- [44] Mejia-Vilet JM, Ramirez V, Cruz C, Uribe N, Gamba G, Bobadilla NA. Renal ischemia-reperfusion injury is prevented by the mineralocorticoid receptor blocker spironolactone.

American Journal of Physiology. Renal Physiology. 2007;**293**(1):F78-F86

[45] Barrera-Chimal J, Perez-Villalva R, Rodriguez-Romo R, et al. Spironolactone prevents chronic kidney disease caused by ischemic acute kidney injury. *Kidney International*. 2013;**83**(1):93-103

[46] Sanchez-Pozos K, Barrera-Chimal J, Garzon-Muvdi J, et al. Recovery from ischemic acute kidney injury by spironolactone administration. *Nephrology, Dialysis, Transplantation*. 2012;**27**(8):3160-3169

[47] Barrera-Chimal J, Estrela GR, Lechner SM, et al. The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling. *Kidney International*. 2018;**93**(6):1344-1355

[48] Barrera-Chimal J, Perez-Villalva R, Ortega JA, et al. Mild ischemic injury leads to long-term alterations in the kidney: Amelioration by spironolactone administration. *International Journal of Biological Sciences*. 2015;**11**(8):892-900

[49] Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. *The Journal of Clinical Investigation*. 1996;**98**(4):1063-1068

[50] Fujihara CK, Kowala MC, Breyer MD, et al. A novel aldosterone antagonist limits renal injury in 5/6 nephrectomy. *Scientific Reports*. 2017;**7**(1):7899

[51] Rocha R, Chander PN, Zuckerman A, Stier CT Jr. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. *Hypertension*. 1999;**33**(1 Pt 2):232-237

[52] Zhou X, Ono H, Ono Y, Frohlich ED. Aldosterone antagonism ameliorates proteinuria and nephrosclerosis

independent of glomerular dynamics in L-NAME/SHR model. *American Journal of Nephrology*. 2004;**24**(2):242-249

[53] Trachtman H, Weiser AC, Valderrama E, Morgado M, Palmer LS. Prevention of renal fibrosis by spironolactone in mice with complete unilateral ureteral obstruction. *The Journal of Urology*. 2004;**172**(4 Pt 2):1590-1594

[54] Chen H, Sun F, Zhong X, Shao Y, Yoshimura A, Liu Y. Eplerenone-mediated aldosterone blockade prevents renal fibrosis by reducing renal inflammation, interstitial cell proliferation and oxidative stress. *Kidney & Blood Pressure Research*. 2013;**37**(6):557-566

[55] Lothar A, Furst D, Bergemann S, et al. Deoxycorticosterone acetate/salt-induced cardiac but not renal injury is mediated by endothelial mineralocorticoid receptors independently from blood pressure. *Hypertension*. 2016;**67**(1):130-138

[56] Aldigier JC, Kanjanbuch T, Ma LJ, Brown NJ, Fogo AB. Regression of existing glomerulosclerosis by inhibition of aldosterone. *Journal of the American Society of Nephrology*. 2005;**16**(11):3306-3314

[57] Miura R, Nakamura K, Miura D, et al. Anti-inflammatory effect of spironolactone on human peripheral blood mononuclear cells. *Journal of Pharmacological Sciences*. 2006;**101**(3):256-259

[58] Kobayashi N, Hara K, Tojo A, et al. Eplerenone shows renoprotective effect by reducing LOX-1-mediated adhesion molecule, PKCepsilon-MAPK-p90RSK, and Rho-kinase pathway. *Hypertension*. 2005;**45**(4):538-544

[59] Arai K, Tsuruoka H, Homma T. CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist,

prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats. *European Journal of Pharmacology*. 2015;**769**:266-273

[60] Shibata S, Nagase M, Yoshida S, et al. Modification of mineralocorticoid receptor function by Rac 1 GTPase: Implication in proteinuric kidney disease. *Nature Medicine*. 2008;**14**(12):1370-1376

[61] Fujisawa G, Okada K, Muto S, et al. Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats. *Kidney International*. 2004;**66**(4):1493-1502

[62] Guo C, Martinez-Vasquez D, Mendez GP, et al. Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus. *Endocrinology*. 2006;**147**(11):5363-5373

[63] Bamberg K, Johansson U, Edman K, et al. Preclinical pharmacology of AZD 9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion. *PLoS One*. 2018;**13**(2):e0193380

[64] Han SY, Kim CH, Kim HS, et al. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. *Journal of the American Society of Nephrology*. 2006;**17**(5):1362-1372

[65] Lachaux M, Barrera-Chimal J, Nicol L, et al. Short- and long-term administration of the non-steroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome-related cardio-renal dysfunction. *Diabetes, Obesity & Metabolism*. 2018;**20**(10):2399-2407

[66] Nielsen FT, Jensen BL, Marcussen N, Skott O, Bie P. Inhibition of mineralocorticoid receptors with eplerenone alleviates short-term

cyclosporin A nephrotoxicity in conscious rats. *Nephrology, Dialysis, Transplantation*. 2008;**23**(9):2777-2783

[67] Feria I, Pichardo I, Juarez P, et al. Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity. *Kidney International*. 2003;**63**(1):43-52

[68] Perez-Rojas JM, Derive S, Blanco JA, et al. Renocortical mRNA expression of vasoactive factors during spironolactone protective effect in chronic cyclosporine nephrotoxicity. *American Journal of Physiology. Renal Physiology*. 2005;**289**(5):F1020-F1030

[69] Waanders F, Rienstra H, Boer MW, et al. Spironolactone ameliorates transplant vasculopathy in renal chronic transplant dysfunction in rats. *American Journal of Physiology. Renal Physiology*. 2009;**296**(5):F1072-F1079

[70] Ma FY, Han Y, Nikolic-Paterson DJ, Kolkhof P, Tesch GH. Suppression of rapidly progressive mouse glomerulonephritis with the non-steroidal mineralocorticoid receptor antagonist BR-4628. *PLoS One*. 2015;**10**(12):e0145666

[71] Gullulu M, Akdag I, Kahvecioglu S, Filiz G, Savci V. Aldosterone blockage in proliferative glomerulonephritis prevents not only fibrosis, but proliferation as well. *Renal Failure*. 2006;**28**(6):509-514

[72] Asai M, Monkawa T, Marumo T, et al. Spironolactone in combination with cilazapril ameliorates proteinuria and renal interstitial fibrosis in rats with anti-Thy-1 irreversible nephritis. *Hypertension Research*. 2004;**27**(12):971-978

[73] Beldhuis IE, Myhre PL, Claggett B, et al. Efficacy and safety of spironolactone in patients with HFpEF and chronic kidney disease. *JACC: Heart Failure*. 2019;**7**(1):25-32